Literature DB >> 12452378

Expression of P-glycoprotein and C-MOAT in human hepatocellular carcinoma: detection by immunostaining.

John Richart1, Elizabeth M Brunt, Adrian M Di Bisceglie.   

Abstract

P-Glycoprotein and C-MOAT are important hepatic transport proteins which play a role in handling anticancer drugs. Hepatocellular carcinoma is a common hepatic malignancy that is relatively resistant to chemotherapeutic drugs. We therefore studied the expression of these two transport proteins in liver sections from hepatocellular carcinoma by immunohistochemistry and compared the reactivity to that in other liver conditions, including cirrhosis and dysplasia. We studied 53 sections from 17 liver specimens and found that the majority of samples stained positively for both P-glycoprotein and C-MOAT; however, the degree of staining was less in HCC and hepatic adenoma than in liver adjacent to HCC or in cirrhosis or dysplastic nodules. HCC with a compact pattern had less staining than those with acinar, scirrhous, or trabecular patterns. The location of both P-glycoprotein and C-MOAT staining was a function of the liver lesion present. Thus, most tissues without hepatocellular carcinoma showed foci of globular canalicular staining, whereas a delicate linear pattern of canalicular staining was most common overall. We conclude that expression of P-glycoprotein and C-MOAT, as detected by qualitative immunohistochemical evaluation are little affected by the development of HCC and therefore are probably of little clinical significance for management of malignancy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12452378     DOI: 10.1023/a:1020543522417

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  9 in total

1.  Expression of a multidrug-resistance gene in human tumors and tissues.

Authors:  A T Fojo; K Ueda; D J Slamon; D G Poplack; M M Gottesman; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

Review 2.  Molecular pathogenesis of cholestasis.

Authors:  M Trauner; P J Meier; J L Boyer
Journal:  N Engl J Med       Date:  1998-10-22       Impact factor: 91.245

Review 3.  Hepatocellular carcinoma.

Authors:  D F Schafer; M F Sorrell
Journal:  Lancet       Date:  1999-04-10       Impact factor: 79.321

Review 4.  Terminology of nodular hepatocellular lesions.

Authors: 
Journal:  Hepatology       Date:  1995-09       Impact factor: 17.425

5.  Overexpression of P-glycoprotein in adenomatous hyperplasia of human liver with cirrhosis.

Authors:  N Nagasue; D K Dhar; Y Makino; H Yoshimura; T Nakamura
Journal:  J Hepatol       Date:  1995-02       Impact factor: 25.083

6.  Characterization of MOAT-C and MOAT-D, new members of the MRP/cMOAT subfamily of transporter proteins.

Authors:  M G Belinsky; L J Bain; B B Balsara; J R Testa; G D Kruh
Journal:  J Natl Cancer Inst       Date:  1998-11-18       Impact factor: 13.506

7.  Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma.

Authors:  T Takayama; M Makuuchi; S Hirohashi; M Sakamoto; N Okazaki; K Takayasu; T Kosuge; Y Motoo; S Yamazaki; H Hasegawa
Journal:  Lancet       Date:  1990-11-10       Impact factor: 79.321

8.  Immunohistochemical study of expression and cellular localization of the multidrug resistance gene product P-glycoprotein in primary liver carcinoma.

Authors:  M Itsubo; T Ishikawa; G Toda; M Tanaka
Journal:  Cancer       Date:  1994-01-15       Impact factor: 6.860

9.  Human hepatocellular carcinoma cell lines exhibit multidrug resistance unrelated to MRD1 gene expression.

Authors:  D W Shen; Y G Lu; K V Chin; I Pastan; M M Gottesman
Journal:  J Cell Sci       Date:  1991-03       Impact factor: 5.285

  9 in total
  1 in total

1.  Expression of Drug-Resistant Factor Genes in Hepatocellular Carcinoma Patients Undergoing Chemotherapy with Platinum Complex by Arterial Infusion.

Authors:  Tomoya Sakurada; Masaharu Yoshikawa; Masahiko Sunaga; Eriko Kobayashi; Nobunori Satoh; Osamu Yokosuka; Shiro Ueda
Journal:  Pharmaceutics       Date:  2010-09-09       Impact factor: 6.321

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.